Published in Surgery on November 01, 1977
Development of a hybrid bioartificial liver. Ann Surg (1993) 1.57
Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg (1997) 1.38
A bioartificial liver to treat severe acute liver failure. Ann Surg (1994) 1.14
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol (2000) 4.33
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst (1998) 3.56
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med (1994) 3.54
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res (1998) 3.39
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet (1996) 2.93
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82
BRCA-associated breast cancer in young women. J Clin Oncol (1998) 2.78
Injuries associated with hang gliding. JAMA (1975) 2.65
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res (2001) 2.53
Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res (1994) 2.46
Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology (2008) 2.44
Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet (1996) 2.40
Heterologous liver perfusion in treatment of hepatic failure. Ann Surg (1965) 2.27
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Talcum Powder Granuloma: A Frequent and Serious Postoperative Complication. Ann Surg (1947) 2.14
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol (2000) 2.13
Evidence for secular trends in children's physical activity behaviour. Br J Sports Med (2005) 2.07
A new venous prosthesis. Surgery (1972) 2.01
Detecting gene copy number fluctuations in tumor cells by microarray analysis of genomic representations. Genome Res (2000) 1.99
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest (1993) 1.94
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol (1999) 1.82
Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep (1977) 1.82
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst (1999) 1.73
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst (1996) 1.70
The Norton-Simon hypothesis revisited. Cancer Treat Rep (1986) 1.70
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol (1998) 1.68
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol (1991) 1.65
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Metastatic hypernephroma to the head and neck. AJNR Am J Neuroradiol (1988) 1.60
Multiple organ failure. Surg Gynecol Obstet (1977) 1.59
The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem (1998) 1.59
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst (1993) 1.56
Factors Affecting Hepatic Vascular Resistance in the Perfused Liver. Ann Surg (1963) 1.53
An experimental analysis of classically conditioned nausea during cancer chemotherapy. Psychosom Med (1992) 1.48
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene (2009) 1.48
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem (2000) 1.47
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat (2001) 1.46
Cholecystectomy with and without surgical drainage. Am J Surg (1975) 1.44
Predicting the course of Gompertzian growth. Nature (1976) 1.39
Endoscopic versus operative gastrostomy: final results of a prospective randomized trial. Gastrointest Endosc (1990) 1.39
The impact of the sequence of radiation and chemotherapy on local control after breast-conserving surgery. Cancer J Sci Am (2006) 1.38
Editorial: Hang gliding. JAMA (1975) 1.38
Peritoneal atrial shunt for intractable ascites. Arch Surg (1967) 1.33
Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia (2000) 1.25
Decision for surgical management of perforation following endoscopic sphincterotomy. Am Surg (1991) 1.25
p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol (1995) 1.24
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Unsuspected depressed cardiac output following blunt thoracic or abdominal trauma. Surgery (1971) 1.23
Liver failure in the postoperative patient: the role of sepsis and immunologic deficiency. Surgery (1975) 1.20
Catalase and superoxide dismutase in Escherichia coli. J Biol Chem (1983) 1.19
Surfing injuries At waikiki. JAMA (1977) 1.19
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol (2000) 1.17
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res (1994) 1.16
Selective plasmapheresis in dogs for delay of heterograft response. Trans Am Soc Artif Intern Organs (1970) 1.14
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol (2006) 1.14
HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Williston Park) (1997) 1.12
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat Rep (1977) 1.12
Duodenal obstruction by the superior mesenteric artery in bedridden combat casualties. Ann Surg (1971) 1.12
Morbidity of colostomy closure. Am J Surg (1976) 1.11
High-fat/low-carbohydrate diet reduces insulin-stimulated carbohydrate oxidation but stimulates nonoxidative glucose disposal in humans: An important role for skeletal muscle pyruvate dehydrogenase kinase 4. J Clin Endocrinol Metab (2006) 1.10
A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol (1987) 1.10
BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res (1998) 1.09
Experimental evaluation of Gore-Tex membrane oxygenator. J Thorac Cardiovasc Surg (1975) 1.07
Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst (1977) 1.07
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol (1996) 1.07
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol (1997) 1.07
The surgical management of atypical mycobacterial soft-tissue infections. Surgery (1990) 1.05
Frequency of NUP98-NSD1 fusion transcript in childhood acute myeloid leukaemia. Leukemia (2003) 1.04
Depression of cell-mediated immunity in diabetes. Arch Surg (1978) 1.04
Precholecystectomy endoscopic cholangiography and stone removal is not superior to cholecystectomy, cholangiography, and common duct exploration. Am J Surg (1992) 1.04
The continuing challenge of duodenal injuries. J Trauma (1978) 1.04
Stress ulcers--a continuing challenge. N Engl J Med (1970) 1.03
Postinjury thoracotomy in the emergency department: a critical evaluation. Surgery (1979) 1.03
Abdominal stab wounds: evaluation of sinography. J Trauma (1976) 1.02
Experimental evaluation of intercostal pedicle grafts in esophageal repair. J Thorac Cardiovasc Surg (1965) 1.02
Treatment of hepatic coma by extracorporeal liver perfusion. Ann R Coll Surg Engl (1966) 1.01
Impaired beta adrenergic receptor binding and function in cystic fibrosis neutrophils. J Clin Invest (1981) 1.01